I
Ikena Oncology
Patient-directed oncology therapies across pathways relevant in tumor and immune cells
About Ikena Oncology
Ikena Oncology is a biotechnology company focused on developing targeted therapies for cancer patients. The company operates in the oncology market, aiming to address the unmet needs of patients by targeting specific nodes of cancer growth, spread, and therapeutic resistance. Ikena's business model revolves around the research and development of differentiated oncology therapies, leveraging a deep institutional knowledge and a broad array of tools to create the right drug for the right patient. The company generates revenue through partnerships, licensing agreements, and the eventual commercialization of its therapies. Ikena serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, all focused on improving cancer treatment outcomes.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Boston, United States
- Listing
- IPO 2021
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 28.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Aug 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Ikena Oncology.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Dec 2024 | $75M | — | Foresite Capital · Deep Track Capital · Blue Owl Capital · OrbiMed | ↗ |
| ACQUISITIONOther financing | Dec 2024 | $0 | — | Inmagene Biopharmaceuticals | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$57M | — |
| 2025 | $0 | — | −$57M | — |
| 2024 | $0 | -100% | −$57M | — |
| 2023 | $9.2M | -41.3% | −$82M | -889.8% |
| 2022 | $16M | -49.6% | −$70M | -449.2% |
| 2021 | $31M | +237% | −$34M | -108.4% |
| 2020 | $9.2M | — | −$44M | -481% |
Growth signals
Latest recorded traffic for Ikena Oncology is 290 monthly website visits, down 90.9% over the last three months. Ikena Oncology's team declined 31.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
Atlas Venture
OrbiMed
Bristol-Myers Squibb
Celgene
Fidelity Investments
Cowen Group
Invus
Omega Funds
BVF Partners
Citadel
Farallon Capital Management- HPHealthCor Partners
Logos Capital
Other known investors6 additional known investors
Blue Owl Capital
Deep Track Capital
Foresite Capital
Inmagene Biopharmaceuticals
RTW Investments
University of Texas at Austin
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ikena Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ikena Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.